ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2168

A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy

Lily Romero Karam1, Kevin Honan1, Salman Arain1 and Maureen Mayes2, 1University of Texas Health Science Center at Houston, Houston, TX, 2Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX

Meeting: ACR Convergence 2022

Keywords: Scleroderma, Systemic sclerosis, Ulcers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: The combination of Raynaud´s Phenomenon (RP) and vasculopathy, characterized by intimal proliferation and fibrosis, endothelial dysfunction, and smooth-muscle activation, can lead to severe digital ischemia in patients with systemic sclerosis (SSc). Despite standard treatments, a subset of patients sustain prolonged disability and experience tissue loss including digital amputation. We describe a new approach that combines vasodilatory therapy and percutaneous intervention to address refractory digital ischemia in patients with SSc.

Methods: This is a single-center, retrospective study of patients fulfilling the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis presenting with digital ulceration, gangrene or severe RP from January 1, 2020, to May 31, 2021 and who underwent percutaneous intervention of the hand and forearm followed by intravenous prostaglandin infusion. Patient demographics and clinical characteristics including manifestations of SSc, antibody profiles, presence of interstitial lung disease and/or pulmonary hypertension were collected by medical record review. Angiographic findings such as location of occlusive lesions and procedural strategies were collected. Outcomes, specifically status of cardinal digital ulceration, and improvement in symptoms as reported by patients, were obtained via progress notes, patient communication and clinical photographs.

Results: Six patients with SSc were included. The age range was 40-63 years, 5/6 subjects were female, 3/6 had past or current smoking history, 3/6 had hypertension, 1/6 peripheral vascular disease. All patients had positive antinuclear antibodies (ANA), 5 in centromere pattern and 1 in a speckled pattern. One patient had both RNP and SS-A antibodies, another had SS-A antibodies. Two patients had SSc sine skin sclerosis, 3 limited cutaneous disease and 1 diffuse cutaneous SSc. Two patients had interstitial lung disease without hypoxia and none had pulmonary arterial hypertension. Disease duration from onset of RP to time of intervention ranged from 3 to 9 years. Five out of 6 patients were on calcium channel blockers and phosphodiesterase inhibitors at the time of the angioplasty; the 6th patient was newly diagnosed and not on medication. (Table 1).

Fourteen percutaneous interventions were performed. Three patients had multiple procedures. Ulnar artery occlusion (UAO) was found in 13/14 angiograms. Most patients presenting with a digital ulceration had healed after the intervention, 2 patients required a repeat intervention for the same lesion. All patients reported symptomatic improvement and none progressed to auto-amputation of the digits. (Table 2) No adverse events from the procedures were reported. Figure 1 shows before and after intervention photographs for one of the patients along with the angiographic findings.

Conclusion: SSc-associated digital ischemia is a cause of significant morbidity. UAO is a prevalent finding in our cohort and highlights the severity of the vasculopathy in SSc patients. Our study shows that percutaneous intervention of the vasculature of the hand is a safe approach which may restore blood flood to the digits, allow wound healing and prevent tissue loss.

Supporting image 1

Table 1. Demographics and Clinical Characteristics of Patients

Supporting image 2

Table 2. Procedural And Clinical Outcomes Following Angioplasty In Scleroderma Patients With Refractory Raynaud’s Phenomenon

Supporting image 3

Figure 1. Left hand of Patient 1. Panel A shows impending skin necrosis at the tips of the 2nd and 3rd digits, prior to procedure 1. Panels C and D show resolution of ischemia after procedure 2. Panel E shows occlusion of the left ulnar artery (arrowheads) and interrupted superficial and deep palmar arches (arrow). After percutaneous transluminal angioplasty of the ulnar occlusion (middle image), the final angiogram shows restoration of antegrade flow into the superficial and deep palmar arches through the patent ulnar artery (arrow).


Disclosures: L. Romero Karam, None; K. Honan, None; S. Arain, None; M. Mayes, Actelion Pharma, Mitsubishi-Tanabe, Boehringer Ingelheim, EICOS, Horizon Pharma, Prometheus, Corbus, Medtelligence.

To cite this abstract in AMA style:

Romero Karam L, Honan K, Arain S, Mayes M. A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-novel-pharmaco-interventional-approach-for-the-treatment-of-refractory-digital-ischemia-in-systemic-sclerosis-percutaneous-revascularization-combined-with-intravenous-vasodilatory-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-pharmaco-interventional-approach-for-the-treatment-of-refractory-digital-ischemia-in-systemic-sclerosis-percutaneous-revascularization-combined-with-intravenous-vasodilatory-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology